Vertical Group

MicroTransponder, Inc. is a medical device company focused on developing and commercializing neurostimulation devices aimed at treating neurological diseases. The company offers innovative therapies, including the Serenity System for tinnitus and the Paired VNS System, which addresses chronic pain and post-stroke upper limb mobility issues. Founded in 2007, MicroTransponder is headquartered in Dallas, Texas, and aims to enhance treatment options for various neurological conditions through its advanced technology.

Carlsmed, founded in 2018 and headquartered in San Diego, California, specializes in developing advanced solutions for the treatment of complex spinal deformities. The company utilizes artificial intelligence, predictive analytics, and advanced imaging technologies through its proprietary Aprevo platform. This platform enables surgeons to create personalized surgical plans and devices tailored to each patient's specific medical needs. By harnessing clinical intelligence and prior outcomes data, Carlsmed aims to improve surgical results while reducing healthcare costs associated with complex spine surgeries. The company's innovative approach is designed to enhance the ability of spine surgeons to achieve better outcomes, ultimately helping patients regain their active lifestyles.

Route 92 Medical, Inc. specializes in developing innovative medical devices aimed at treating acute ischemic stroke and related conditions. The company has created a stealthy catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery system. These products are designed to assist healthcare professionals in effectively treating strokes and enhancing patient recovery. Founded in 2015 and based in San Mateo, California, Route 92 Medical continues to focus on advancing technologies that improve outcomes for stroke patients.

Carlsmed, founded in 2018 and headquartered in San Diego, California, specializes in developing advanced solutions for the treatment of complex spinal deformities. The company utilizes artificial intelligence, predictive analytics, and advanced imaging technologies through its proprietary Aprevo platform. This platform enables surgeons to create personalized surgical plans and devices tailored to each patient's specific medical needs. By harnessing clinical intelligence and prior outcomes data, Carlsmed aims to improve surgical results while reducing healthcare costs associated with complex spine surgeries. The company's innovative approach is designed to enhance the ability of spine surgeons to achieve better outcomes, ultimately helping patients regain their active lifestyles.

Biorez, Inc. is a medical device company focused on developing bioresorbable scaffold implants designed to regenerate functional tissue in vivo. The company’s lead product is an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and offers a superior alternative to cadaver-based materials. Biorez utilizes patented technology involving a degradable polymer for its orthopedic implants, including the L-C Ligament and biorez GRAFT, an FDA-cleared device for soft tissue augmentation of the rotator cuff. Founded in 2008 and based in New Haven, Connecticut, Biorez aims to commercialize its ACL technology while expanding its platform for innovative clinical solutions.

Biorez, Inc. is a medical device company focused on developing bioresorbable scaffold implants designed to regenerate functional tissue in vivo. The company’s lead product is an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and offers a superior alternative to cadaver-based materials. Biorez utilizes patented technology involving a degradable polymer for its orthopedic implants, including the L-C Ligament and biorez GRAFT, an FDA-cleared device for soft tissue augmentation of the rotator cuff. Founded in 2008 and based in New Haven, Connecticut, Biorez aims to commercialize its ACL technology while expanding its platform for innovative clinical solutions.

Biorez, Inc. is a medical device company focused on developing bioresorbable scaffold implants designed to regenerate functional tissue in vivo. The company’s lead product is an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and offers a superior alternative to cadaver-based materials. Biorez utilizes patented technology involving a degradable polymer for its orthopedic implants, including the L-C Ligament and biorez GRAFT, an FDA-cleared device for soft tissue augmentation of the rotator cuff. Founded in 2008 and based in New Haven, Connecticut, Biorez aims to commercialize its ACL technology while expanding its platform for innovative clinical solutions.

Hinge Health, Inc. specializes in digital healthcare solutions designed to assist employees in recovering from musculoskeletal disorders. Founded in 2015 and headquartered in San Francisco, the company offers a Digital Clinic that integrates sensor technology with physical therapy guidance and support services. Hinge Health's solutions, which include sensor bands and tablet computers, focus on treating chronic back and joint pain, helping to reduce opioid use and the need for surgeries. The company serves nearly 200 enterprise customers, positioning itself as a leading provider of musculoskeletal solutions for employers and health plans. In addition to its San Francisco headquarters, Hinge Health has offices in Chicago, Minneapolis, Portland, and London.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing innovative solutions for carotid artery disease. The company specializes in transcarotid artery revascularization (TCAR), a minimally invasive approach designed to reduce the risk of stroke during surgical interventions. Its product lineup includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery and allows for temporary blood flow reversal to protect the brain. Additionally, the ENROUTE Transcarotid Stent System is a self-expanding stent backed by clinical evidence supporting its safety outcomes. Other offerings include the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire for guiding interventional devices. Founded in 2007, Silk Road Medical aims to improve patient care through collaboration with vascular specialists and ongoing innovation in vascular therapies.

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

Home Dialysis Plus, Ltd. provides home hemodialysis solutions to patients and their healthcare providers. Its dialysis system enables hemodialysis treatment in the homes of patients. Home Dialysis Plus, Ltd. was founded in 2003 and is based in Portland, Oregon.

Hinge Health, Inc. specializes in digital healthcare solutions designed to assist employees in recovering from musculoskeletal disorders. Founded in 2015 and headquartered in San Francisco, the company offers a Digital Clinic that integrates sensor technology with physical therapy guidance and support services. Hinge Health's solutions, which include sensor bands and tablet computers, focus on treating chronic back and joint pain, helping to reduce opioid use and the need for surgeries. The company serves nearly 200 enterprise customers, positioning itself as a leading provider of musculoskeletal solutions for employers and health plans. In addition to its San Francisco headquarters, Hinge Health has offices in Chicago, Minneapolis, Portland, and London.

Route 92 Medical, Inc. specializes in developing innovative medical devices aimed at treating acute ischemic stroke and related conditions. The company has created a stealthy catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery system. These products are designed to assist healthcare professionals in effectively treating strokes and enhancing patient recovery. Founded in 2015 and based in San Mateo, California, Route 92 Medical continues to focus on advancing technologies that improve outcomes for stroke patients.

Biorez, Inc. is a medical device company focused on developing bioresorbable scaffold implants designed to regenerate functional tissue in vivo. The company’s lead product is an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and offers a superior alternative to cadaver-based materials. Biorez utilizes patented technology involving a degradable polymer for its orthopedic implants, including the L-C Ligament and biorez GRAFT, an FDA-cleared device for soft tissue augmentation of the rotator cuff. Founded in 2008 and based in New Haven, Connecticut, Biorez aims to commercialize its ACL technology while expanding its platform for innovative clinical solutions.

Suture Concepts provides better solutions for soft tissue management.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing innovative solutions for carotid artery disease. The company specializes in transcarotid artery revascularization (TCAR), a minimally invasive approach designed to reduce the risk of stroke during surgical interventions. Its product lineup includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery and allows for temporary blood flow reversal to protect the brain. Additionally, the ENROUTE Transcarotid Stent System is a self-expanding stent backed by clinical evidence supporting its safety outcomes. Other offerings include the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire for guiding interventional devices. Founded in 2007, Silk Road Medical aims to improve patient care through collaboration with vascular specialists and ongoing innovation in vascular therapies.

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.

Suture Concepts provides better solutions for soft tissue management.

Monteris Medical develops and markets advanced medical devices for minimally invasive neurosurgery, focusing on the treatment of brain diseases. Their flagship product, the NeuroBlate System, utilizes MRI-guided laser thermotherapy for the precise ablation of pathological brain lesions, including both primary and metastatic tumors. This innovative system allows neurosurgeons to deliver focused laser energy directly to tumors while minimizing damage to surrounding healthy tissue, offering real-time control and visualization during procedures. Monteris Medical also provides stereotactic anchoring devices for accurate image-guided trajectory alignment and AtamA stabilization systems for MR-based procedures requiring head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company distributes its products through sales representatives to neurosurgeons across the United States. Formerly known as AutoLITT, Monteris Medical has established itself as a leader in the development of technologies aimed at improving the treatment of brain cancer.

Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.

AtheroMed, Inc. develops treatments for peripheral arterial disease. The company was incorporated in 2006 and is headquartered in Menlo Park, California.

Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing innovative solutions for carotid artery disease. The company specializes in transcarotid artery revascularization (TCAR), a minimally invasive approach designed to reduce the risk of stroke during surgical interventions. Its product lineup includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery and allows for temporary blood flow reversal to protect the brain. Additionally, the ENROUTE Transcarotid Stent System is a self-expanding stent backed by clinical evidence supporting its safety outcomes. Other offerings include the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire for guiding interventional devices. Founded in 2007, Silk Road Medical aims to improve patient care through collaboration with vascular specialists and ongoing innovation in vascular therapies.

AtheroMed, Inc. develops treatments for peripheral arterial disease. The company was incorporated in 2006 and is headquartered in Menlo Park, California.

Flexuspine operates as a spine company. It offers a spinal segment replacement to provide an alternative to lumbar fusion by re-establishing mobility to an affected segment of the lumbar spine. The company’s functional spinal unit is a comprehensive device composed of an interbody disc component and posterior dynamic resistance component to replace the natural kinematics of the motion segment. Flexuspine was founded on 2003 and is based in Pittsburgh, Pennsylvania.

Suture Concepts provides better solutions for soft tissue management.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.

At ENTrigue Surgical, we're rethinking established Otolaryngology techniques to develop innovative instruments, materials, and medical devices that make sinus surgery more efficient, effective, and comfortable for patients.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several monoclonal antibodies, including Navicixizumab, which targets Delta-like ligand 4 and vascular endothelial growth factor, currently undergoing clinical trials for various advanced solid tumors, including metastatic colorectal cancer and platinum-resistant ovarian cancer. Another key candidate, Etigilimab, targets the immunological receptor TIGIT and is in Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed's research also includes preclinical programs focused on additional therapeutic candidates. The company has formed strategic alliances with prominent pharmaceutical firms to enhance its development efforts in creating novel small molecule therapeutics and biologics aimed at cancer treatment. Founded in 2004 and based in Redwood City, California, OncoMed operates as a subsidiary of Mereo BioPharma Group plc.

ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.

Proteolix is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies targeting protein degradation pathways to address cancer and autoimmune diseases. The company’s lead product is a pioneering proteasome inhibitor, designed to evaluate safety and efficacy in treating multiple myeloma and various malignancies. In addition to this lead product, Proteolix is advancing a pipeline of novel proteasome inhibitors, which includes an oral formulation and a selective immunoproteasome inhibitor. These therapies aim to provide healthcare professionals with effective treatment options for specific hematologic cancers by inhibiting the cellular proteasome.

Meritage Pharma, Inc. is a company focused on developing prescription products for gastrointestinal and atopic diseases. Founded in 2008 and based in San Diego, California, it specializes in budesonide, a glucocorticoid steroid used in treatments for conditions such as pediatric asthma, allergic rhinitis, and Crohn's disease. The company's primary product candidate is an oral budesonide suspension aimed at treating adolescents and young adults with eosinophilic esophagitis, an allergic inflammation affecting the gastrointestinal tract. Through its innovative approaches, Meritage Pharma seeks to address significant medical needs in these areas.

Tepha, Inc. is a medical device company based in Lexington, Massachusetts, specializing in the development and manufacture of components utilizing proprietary biomaterial technology. The firm focuses on producing a new class of absorbable biomaterials known as polyhydroxyalkanoates (PHAs), which are engineered with recombinant DNA technology. Tepha's product offerings include monofilament sutures and meshes designed for various surgical applications, such as soft tissue approximation, hernia repair, and pelvic floor reconstruction. Additionally, the company provides the P4HB regenerative polymer scaffold for treating stress urinary incontinence, along with surgical films and composite meshes that facilitate tissue attachment and minimize complications. Tepha aims to address unmet medical needs across multiple fields by offering innovative solutions characterized by superior flexibility, elasticity, biocompatibility, and strength retention.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides for medical applications. The company focuses on creating proprietary therapeutic peptides and implantable devices designed to enhance bone and soft tissue repair, particularly in orthobiologics. Its flagship product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, serving as a surgical bone graft implant for various spinal and orthopedic surgeries, including lumbar degenerative disc disease and foot and ankle fusion procedures. Additionally, BioSET develops products for sports medicine and offers peptide signaling molecules along with diverse scaffold biomaterials to support musculoskeletal applications, including trauma and fracture repair. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that focuses on developing innovative solutions for carotid artery disease. The company specializes in transcarotid artery revascularization (TCAR), a minimally invasive approach designed to reduce the risk of stroke during surgical interventions. Its product lineup includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery and allows for temporary blood flow reversal to protect the brain. Additionally, the ENROUTE Transcarotid Stent System is a self-expanding stent backed by clinical evidence supporting its safety outcomes. Other offerings include the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire for guiding interventional devices. Founded in 2007, Silk Road Medical aims to improve patient care through collaboration with vascular specialists and ongoing innovation in vascular therapies.

Bacchus Vascular, Inc. offers medical devices for the treatment of occlusive vascular disease to interventional radiologists and vascular surgeons in the United States. It provides the TRELLIS-8 Peripheral Infusion System, an isolated thrombolysis catheter that enables treatment of deep vein thrombosis and arterial occlusions by targeted delivery of clot-dissolving drugs. The company was founded in 1999 and is based in Santa Clara, California.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Galil Medical is a new era of minimally invasive cryotherapy solutions that enhance patient quality of life. Galil Medical’s technology involves freezing and ablating diseased tissue in a technique referred to as cryotherapy, also referred to as cryoablation and cryosurgery. Galil Medical cryotherapy systems use compressed Argon gas to produce extremely low temperatures. As the gas passes through the cryoablation needle, the tip of the needle is cooled, forming an iceball, which engulfs the tumor and destroys the tissue. A variety of needle types is available to sculpt a freeze zone conformed to the tumor size and shape. Galil Medical cryosurgical systems precisely deliver sub-zero temperatures to target tissue with the aid of patented 17-gauge cryoablation needles and high-resolution imaging for the cryosurgical ablation of benign and cancerous tumors. Cryotherapy ablation has been widely used for prostate cancer treatment and kidney cancer treatment. New ablation treatments for various other tumors are being developed in the Women’s Health and Interventional Radiology markets.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

Suture Concepts provides better solutions for soft tissue management.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several monoclonal antibodies, including Navicixizumab, which targets Delta-like ligand 4 and vascular endothelial growth factor, currently undergoing clinical trials for various advanced solid tumors, including metastatic colorectal cancer and platinum-resistant ovarian cancer. Another key candidate, Etigilimab, targets the immunological receptor TIGIT and is in Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed's research also includes preclinical programs focused on additional therapeutic candidates. The company has formed strategic alliances with prominent pharmaceutical firms to enhance its development efforts in creating novel small molecule therapeutics and biologics aimed at cancer treatment. Founded in 2004 and based in Redwood City, California, OncoMed operates as a subsidiary of Mereo BioPharma Group plc.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions. The company focuses particularly on peripheral vascular disease, which results from reduced or lost blood flow due to arterial narrowing or closure. Founded in October 1997 by Dr. Thomas J. Fogarty, a prominent surgeon and inventor, Vascular Architects has a strong management team with extensive expertise in technical, clinical, and business fields. The company also benefits from the insights of key opinion leaders in interventional and vascular surgery, who serve on its Scientific Advisory Board. In addition to vascular devices, the company produces various intraoperative vascular instruments and monitors used in multiple surgical specialties, including cardiovascular, urological, and neurological procedures.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides for medical applications. The company focuses on creating proprietary therapeutic peptides and implantable devices designed to enhance bone and soft tissue repair, particularly in orthobiologics. Its flagship product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, serving as a surgical bone graft implant for various spinal and orthopedic surgeries, including lumbar degenerative disc disease and foot and ankle fusion procedures. Additionally, BioSET develops products for sports medicine and offers peptide signaling molecules along with diverse scaffold biomaterials to support musculoskeletal applications, including trauma and fracture repair. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

OsteoBiologics is a biotechnology company. It engages in the development and manufacture of bio-absorbable polymeric scaffolds, films, and related instrumentations for the repair and replacement of bone, soft tissue, and articular cartilage. It provides ACTAEON, a tissue evaluation system, which determines the degree and scope of articular cartilage degeneration. It also manufactures custom parts. OsteoBiologics was founded in 1993 and is headquartered in San Antonio, Texas.

Bacchus Vascular, Inc. offers medical devices for the treatment of occlusive vascular disease to interventional radiologists and vascular surgeons in the United States. It provides the TRELLIS-8 Peripheral Infusion System, an isolated thrombolysis catheter that enables treatment of deep vein thrombosis and arterial occlusions by targeted delivery of clot-dissolving drugs. The company was founded in 1999 and is based in Santa Clara, California.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions. The company focuses particularly on peripheral vascular disease, which results from reduced or lost blood flow due to arterial narrowing or closure. Founded in October 1997 by Dr. Thomas J. Fogarty, a prominent surgeon and inventor, Vascular Architects has a strong management team with extensive expertise in technical, clinical, and business fields. The company also benefits from the insights of key opinion leaders in interventional and vascular surgery, who serve on its Scientific Advisory Board. In addition to vascular devices, the company produces various intraoperative vascular instruments and monitors used in multiple surgical specialties, including cardiovascular, urological, and neurological procedures.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides for medical applications. The company focuses on creating proprietary therapeutic peptides and implantable devices designed to enhance bone and soft tissue repair, particularly in orthobiologics. Its flagship product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, serving as a surgical bone graft implant for various spinal and orthopedic surgeries, including lumbar degenerative disc disease and foot and ankle fusion procedures. Additionally, BioSET develops products for sports medicine and offers peptide signaling molecules along with diverse scaffold biomaterials to support musculoskeletal applications, including trauma and fracture repair. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.